NCT06496009View on ClinicalTrials.gov

The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients

Not yet recruitingOBSERVATIONAL

Enrollment

845

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

April 28, 2026

Study Completion Date

April 28, 2027

Conditions

NSCLC

Interventions

DRUG

PD-1 Inhibitors

advanced or metastatic non-small cell lung cancer who are PD-L1 negative and receiving first-line immunotherapy in routine clinical practice

All Listed Sponsors

lead

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

NCT06496009 - The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC Patients | Biotech Hunter | Biotech Hunter